MEDIA | Stockhead

Avecho has been featured in a feature article in Stockhead, on the state of the ASX healthcare sector.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gave his take on the ASX healthcare sector for the week and his ‘Powerplay’ stock pick.

He highlighted Avecho’s recently signed development and licensing agreement with Sandoz Group AG:

“Under the deal Avecho is eligible for development milestone payments totalling US$16m prior to commercialisation and will receive tiered royalties ranging from 14% to 19% on net sales once on market.

Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a right of first refusal to exceed any commercial offers Avecho receives.

“They’re running a major trial with around 250 people in Australia,” Power said.”

Read the article